Martin J Nazzaro

8192408, Jun 5, 2012

Feb 10, 2010

12/703634

Martin Nazzaro - Quincy MA, US
Hong Guo - Wayland MA, US
Ron LeBlanc - Hopedale MA, US
Josh York - Ipswich MA, US

pSivida US, Inc. - Watertown MA

A61M 5/32

604272, 604289, 604294

The invention provides a trocar assembly for delivering a payload into tissue, such as an eye, comprising a primary housing, a cannula, a payload, an actuator and a trocar.

20080071246, Mar 20, 2008

Sep 12, 2007

11/900907

Martin Nazzaro - Quincy MA, US
Hong Guo - Belmont MA, US
Ron LeBlanc - Hopedale MA, US
Josh York - Ipswich MA, US

pSivida Inc. - Watertown MA

A61M 5/178

604506000, 604060000

Disclosed herein is an injector device including an inserter element, a head element, an implant and a set of detachable protector elements for secured device handling. The device comprises a stop that controls the penetration depth of the device during injection. The device may comprise a removable catch that prevents the implant from exiting the device due to the advancement of its inserter element. The device may comprise a disengageable block that prevents the implant from exiting the device from its head element. The device may be configured for intraocular drug delivery.

20120238993, Sep 20, 2012

Dec 21, 2011

13/333731

Martin Nazzaro - Quincy MA, US
Josh York - Ipswich MA, US
Paul Ashton - Newton MA, US

A61M 5/00
B23P 17/04

604500, 604 59, 29428

The invention provides a drug delivery device for one or more drugs. The device has a drug core which is surrounded by an internal and external sheath. The external sheath has a first cap that is permeable to at least one drug in the core. The first cap may comprise polyvinyl alcohol (PVA), and the PVA may be heat cured. In certain aspects, there are one or more additional caps on the ends of the sheaths formed from one or more polymers. In certain aspects, one or more portions of the drug delivery device are substantially impermeable to one or more drugs in the drug core. In certain aspects, the drug elutes through the first cap into a biological environment. The invention further provides methods for manufacturing the drug delivery device.

20120238994, Sep 20, 2012

Dec 21, 2011

13/333743

Martin Nazzaro - Quincy MA, US
Josh York - Ipswich MA, US
Paul Ashton - Newton MA, US

A61M 5/00
B23P 17/04

604500, 604 57, 29428

The invention provides a drug delivery device for latanoprost or latanoprost acid. The device has a core of latanoprost or latanoprost acid which is surrounded by an internal and external sheath. The external sheath has a first cap that is permeable to latanoprost or latanoprost acid. The first cap may comprise polyvinyl alcohol (PVA), and the PVA may be heat cured. In certain aspects, there are one or more additional caps on the ends of the sheaths formed from one or more polymers. In certain aspects, one or more portions of the drug delivery device is substantially impermeable to latanoprost or latanoprost acid. In certain aspects, the latanoprost or latanoprost acid elutes through the first cap into a biological environment. The invention further provides methods for manufacturing the drug delivery device.

20220226544, Jul 21, 2022

Jan 14, 2022

17/576635

- Newton MA, US
Paul Ashton - San Diego CA, US
Martin Nazzaro - Quincy MA, US

A61L 27/54
A61F 2/28
A61K 31/573
A61L 27/06
A61L 27/18

Provided herein are devices and methods for treating inflammation and pain of articular joints (e.g., the knee). An implantable device includes an elongate body extending from a proximal end to a distal end, a flange disposed at the proximal end, a bore extending from an opening at the proximal end into the elongate body, one or more fixation members disposed on an outer surface of the elongate body, and a payload (e.g., a drug-polymer core) having a therapeutic agent disposed within the bore. The payload has a substantially constant surface area on an exposed portion throughout elution of the therapeutic agent after the implantable device is implanted in a body. The therapeutic agent is configured to elute using zero-order kinetics, constantly and continuously at an amount that is above a predetermined lower threshold and does not exceed a predetermined upper threshold unlike a pulse-dose injection.

20160074213, Mar 17, 2016

Sep 10, 2015

14/850374

Martin Nazzaro - Quincy MA, US
Josh York - Ipswich MA, US
Ron Leblanc - Hopedale MA, US

A61F 9/00

The devices and methods described herein relate to injector devices for delivering payloads to a tissue.

20140309610, Oct 16, 2014

Mar 12, 2014

14/206823

- Watertown MA, US
Hong Guo - Wayland MA, US
Martin Nazzaro - Quincy MA, US
Christian Barnett - Pershore, GB

pSivida Corp. - Watertown MA

A61M 31/00
B65B 29/02
A61K 9/48

604500, 604286, 53471

This application provides a device for delivering a beneficial substance to a patient. The device comprises a shell enclosing a plurality of carrier particles. The carrier particles are porous, and a beneficial substance, such as a drug, is disposed in the pores. The drug can diffuse out of the pores, into the interior of the device, and then through at least one permeable portion of the shell. This application also provides methods of making and using these devices.